Day: February 19, 2024

As rates of pediatric myopia (nearsightedness) continue to climb worldwide, families and eye care professionals are eagerly seeking effective interventions. Among the newer solutions entering the market is repeated low-level red light therapy. Promising to slow down myopia progression, these compact devices have quickly gained traction in clinics and homes alike.

However, behind the promising headlines, a critical question remains: Are these devices safe for daily eye exposure?

A quality improvement study conducted by researchers at the University of Houston and published in JAMA Ophthalmology evaluated several popular red light therapy units against established safety standards. Here is a breakdown of what the research uncovered and what it means for consumers.

Assessing the Safety Standards

To test whether these devices pose potential risks to the retina, researchers evaluated four commercially available instruments used for myopia management: the Sky-n1201, Future Vision, EyeRising, and AirDoc.

The devices were tested using parameters established by the American National Standards Institute (ANSI) to determine how long an eye could safely be exposed to their light emission before reaching Group 1 safety limits.

Key Findings: Lasers vs. LEDs

The study revealed a stark contrast in safety profiles based on the underlying technology of each device:

• Laser-Based Devices: Instruments relying on red laser light crossed official safety thresholds in a matter of seconds under standard testing conditions.
  • The EyeRising device reached maximum ANSI safety limits in just 1.4 seconds.
  • The Sky-n1201 reached safety limits in 2.8 seconds.
  • Both devices surpassed allowable limits long before the standard recommended treatment session of 180 seconds was complete.
• LED-Based Devices: In contrast, the AirDoc device, which utilizes light-emitting diodes (LEDs) rather than lasers, delivered a much broader, diffuse illumination. It remained well within safe limits even during extended exposure times exceeding 22,000 seconds.

What This Means for the Future of Myopia Management

While red light therapy holds potential as a non-invasive treatment option, these findings emphasize that not all devices are built equal. High-intensity laser devices can deliver concentrated energy to delicate retinal tissues far more rapidly than gentle LED-based equipment.

With emerging clinical reports noting potential ocular risks—and regulatory agencies in regions like China moving to reclassify red laser devices as Class III medical tools—there is a growing consensus in the optical community: independent, rigorous safety validation is essential before these products see widespread pediatric use.

The Takeaway

If you are considering or currently using red light therapy for myopia control, safety should always come first. Consult directly with an optometrist or ophthalmologist to discuss verified, evidence-based treatments and ensure any equipment used meets strict safety certifications.

For more technical details and exact radiometric data, read the complete study in JAMA Ophthalmology.

With childhood myopia (nearsightedness) on the rise globally, eye care researchers are actively searching for safe, non-invasive ways to slow down eye elongation in young patients. While repeated low-level red light therapy has generated significant interest, concerns around high-energy laser exposure have prompted scientists to look toward gentler alternatives.

A 3-month exploratory randomized clinical trial published in Ophthalmology and Therapy investigated whether low-intensity, non-coherent LED-based photobiomodulation (PBM-LED) can offer a safer profile while still helping manage myopia progression in children.

What Was the Study Testing?

Researchers evaluated a desktop LED-based device (AI-PBM01 / AirDoc) in a double-masked trial involving 40 myopic children aged 8 to 12.

Unlike traditional high-power laser units, this LED device was designed with specific safety parameters in mind:

• Diffuse Energy Output: Uses non-coherent light-emitting diodes (LEDs) rather than concentrated laser beams.

• Targeted Design: Uses an annular light pattern that targets the parafoveal region while avoiding direct irradiation to the central retina (fovea).

• Treatment Schedule: Participants used the desktop device at home for 3 minutes twice daily over a 3-month period.

Key Findings: Safety vs. Treatment Effect

The exploratory trial provided valuable insights into both the safety margins and the early effectiveness of LED-based light therapy:

1. Excellent Safety Profile

Safety was a primary focus of the trial, and the LED device performed exceptionally well:

• No Retinal Damage: Advanced OCT imaging revealed zero structural retinal abnormalities or ocular tissue damage across all participants.

• No Serious Adverse Events: No participants experienced severe side effects or had to discontinue the treatment due to adverse reactions.

• ANSI Group 1 Safety: The diffuse LED light source remained well within official optical safety limits, even under extended exposure conditions.

2. Preliminary, Modest Efficacy

When evaluating how well the device slowed myopia progression (measured by axial length elongation and refractive changes):

• Eye-Specific Differences: The active treatment group showed less axial elongation compared to the control group, reaching nominal statistical significance in the left eye at 3 months.

• Overall Trend: While participant-level averages pointed in a positive direction, the adjusted overall differences between the treatment and control groups were modest and did not reach full statistical significance.

What Does This Mean for the Future of Myopia Control?

The findings suggest that LED-based photobiomodulation is a promising, safety-first alternative to high-power red lasers. By using lower energy and avoiding direct foveal exposure, LED devices eliminate many of the retinal safety risks currently associated with laser-based red light treatments.

However, because the treatment effect was subtle and the study lasted only 3 months, researchers emphasize that larger, long-term clinical trials are necessary to determine whether LED photobiomodulation can deliver lasting, clinically meaningful results for childhood myopia.

The Bottom Line

LED-based red light therapy offers an encouraging glimpse into safer myopia interventions, but it is not a quick fix. Parents and practitioners should view it as an emerging technology that requires further long-term verification.

Always consult an optometrist or ophthalmologist to discuss established, evidence-based options for managing your child’s myopia.

Read the full open-access study in Ophthalmology and Therapy.